Evidence map›Paper›PMID 27646425›Full record

Trial reportAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2016

C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, Kai-Uwe Eckardt, Reshma Kewalramani, Andrew S Levey, John J V McMurray, Patrick Parfrey, Giuseppe Remuzzi, Ajay K Singh and 3 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Interventions for fatigue in people with kidney failure requiring dialysis.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Advances in aptamer-based sensing assays for C-reactive protein.Analytical and bioanalytical chemistry · 2022
    Review
  9. Review
  10. Slipping Through the Pores: Hypoalbuminemia and Albumin Loss During Hemodialysis.International journal of nephrology and renovascular disease · 2021
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Lipid management in patients with chronic kidney disease.Nature reviews. Nephrology · 2018 · on this map
    Review
  18. Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 6 countries.

Finnian R Mc CauslandRenal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: fmccausland@partners.org.
Brian ClaggettHarvard Medical School, Boston, MA; Cardiology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Emmanuel A BurdmannDivision of Nephrology, University of Sao Paulo Medical School, Sao Paulo, Brazil.
Kai-Uwe EckardtDepartment of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany.
Reshma KewalramaniGlobal Clinical Development, Amgen, Thousand Oaks, CA.
Andrew S LeveyDivision of Nephrology, Tufts Medical Center, Boston, MA.
John J V McMurrayInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland.
Patrick ParfreyHealth Sciences Centre, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
Giuseppe RemuzziIRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy; Unit of Nephrology and Dialysis, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
Ajay K SinghRenal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA.
Scott D SolomonHarvard Medical School, Boston, MA; Cardiology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Robert D TotoRenal Division, University of Texas Southwestern, Dallas, TX.
Marc A PfefferHarvard Medical School, Boston, MA; Cardiology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Brigham and Women's Hospital · USAmgen (United States) · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEHarvard University · USMemorial University of Newfoundland · CAThe University of Texas Southwestern Medical Center · USTufts Medical Center · USUniversidade de São Paulo · BRUniversity of Glasgow · GBUniversity of Milan · IT

Funding

Cardiac Complications of Hemodynamic Instability during HemodialysisK23DK102511 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI MCCAUSLAND, FINNIAN R · 2015 to 2019
$964k
NIDDK NIH HHS K23 DK102511
6 · The paper itself

Abstract

backgroundTo better understand a potential association of elevated C-reactive protein (CRP) level with progression of chronic kidney disease (CKD), we examined the relationship of CRP level with the development of end-stage renal disease (ESRD) in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). STUDY

designPost hoc analysis of a randomized controlled trial. SETTING &

participants4,038 patients with type 2 diabetes, CKD, and anemia in TREAT. PREDICTOR: Baseline serum CRP concentrations. OUTCOMES: The primary outcome was development of ESRD; secondary outcomes included doubling of serum creatinine level, a composite of ESRD/serum creatinine doubling, and a composite of death or ESRD. MEASUREMENTS: We fit unadjusted and adjusted Cox regression models to test the association of baseline CRP level with time to the development of the outcomes of interest.

resultsMean age of participants was 67 years, 43% were men, and 64% were white. Approximately half (48%) the patients had CRP levels > 3.0mg/L; 668 patients developed ESRD, and 1,270 developed the composite outcome of death or ESRD. Compared with patients with baseline CRP levels ≤ 3.0mg/L, those with moderately/markedly elevated CRP levels (≥6.9mg/L; 24% of patients) had a higher adjusted risk for ESRD (HR, 1.32; 95% CI, 1.07-1.63) and the composite outcome of death or ESRD (HR, 1.41; 95% CI, 1.21-1.64). Although nonsignificant, similar trends were noted in competing-risk models. LIMITATIONS: Results may not be generalizable to nondiabetic CKD or diabetic CKD in the absence of anemia.

conclusionsElevated baseline CRP levels are common in type 2 diabetic patients with anemia and CKD and are associated with the future development of ESRD and the composite of death or ESRD.

Indexed as

AgedCardiovascular DiseasesC-Reactive ProteinDarbepoetin alfaDouble-Blind MethodFemaleHematinicsHumansKidney Failure, ChronicMaleProspective StudiesRisk AssessmentC-Reactive ProteinDarbepoetin alfaHematinicsanemiabiomarkerchronic kidney disease (CKD)C-Reactive protein (CRP)disease progressionend-stage renal disease (ESRD)inflammationkidney function trajectorymortalityrisk factorserum creatininetype 2 diabetes mellitus (T2DM)

Identifiers

PMID27646425
PMCPMC5123931
OpenAlexW2520298661

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.